Iovance Biotherapeutics Reports Strong Q4 Results, Highlights Pipeline Progress

Company sees accelerating demand for AMTAGVI cell therapy, extended cash runway, and upcoming milestones.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Iovance Biotherapeutics (NASDAQ:IOVA) reported strong fourth-quarter and full-year 2025 results, highlighting accelerating commercial demand for its tumor-infiltrating lymphocyte (TIL) cell therapy AMTAGVI, progress across its pipeline, and an extended cash runway driven by operational optimization.

Why it matters

Iovance's success with AMTAGVI and its pipeline advancements, including Fast Track designation for lifileucel in non-small cell lung cancer, demonstrate the company's ability to drive innovation in the rapidly evolving cell therapy landscape. The strong financial performance and extended cash runway also position Iovance to continue investing in its pipeline and commercial efforts.

The details

Interim CEO Dr. Frederick Vogt said Iovance delivered 30% revenue growth and its "best-ever" 50% margin from cost of sales in Q4 2025, driven by AMTAGVI adoption and cost discipline. The company ended the year with $303 million in cash, expected to fund operations into Q3 2027. Chief Commercial Officer Dan Kirby cited expanding the Authorized Treatment Center network, penetrating the community market, and increasing earlier use of AMTAGVI as key drivers of commercial progress. The company also highlighted pipeline advancements, including Fast Track designation for lifileucel in non-squamous non-small cell lung cancer and promising early data in sarcoma.

  • Iovance reported its Q4 and full-year 2025 results on February 27, 2026.
  • The company implemented a 9% price increase on both AMTAGVI and Proleukin products effective February 1, 2026.

The players

Iovance Biotherapeutics

A clinical-stage biotechnology company specializing in the development and commercialization of tumor-infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors.

Dr. Frederick Vogt

Interim CEO and President of Iovance Biotherapeutics.

Dan Kirby

Chief Commercial Officer of Iovance Biotherapeutics.

AMTAGVI

Iovance's lead TIL cell therapy product candidate.

Lifileucel

Iovance's TIL therapy in late-stage clinical development for patients with advanced melanoma.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

Iovance expects to provide revenue guidance for 2026 in the near future and plans to initiate a single-arm registrational trial for its sarcoma program 'as soon as possible'.

The takeaway

Iovance's strong financial and operational performance, coupled with its pipeline advancements, position the company to continue driving innovation in the cell therapy space and delivering on its mission to bring transformative treatments to cancer patients.